TY - JOUR T1 - Sensitivity to missing not at random dropout in clinical trials: use and interpretation of the Trimmed Means Estimator JF - medRxiv DO - 10.1101/2021.03.05.21252334 SP - 2021.03.05.21252334 AU - Audinga-Dea Hazewinkel AU - Jack Bowden AU - Kaitlin H. Wade AU - Tom Palmer AU - Nicola Wiles AU - Kate Tilling Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252334.abstract N2 - Outcome values in randomized controlled trials (RCTs) may be missing not at random (MNAR), if patients with extreme outcome values are more likely to drop out (e.g., due to perceived ineffectiveness of treatment, or adverse effects). In such scenarios, estimates from complete case analysis (CCA) and multiple imputation (MI) will be biased. The trimmed means (TM) estimator operates by setting missing values to the most extreme value, and then “trimming” away equal fractions of both treatment groups, estimating the treatment effect using the remaining data. The TM estimator relies on two assumptions, which we term the “strong MNAR” and “location shift” assumptions. In this article, we derive formulae for the bias resulting from the violation of these assumptions for normally distributed outcomes. We propose an adjusted estimator, which relaxes the location shift assumption and detail how our bias formulae can be used to establish the direction of bias of CCA, MI and TM estimates under a range of plausible data scenarios, to inform sensitivity analyses. The TM approach is illustrated with simulations and in a sensitivity analysis of the CoBalT RCT of cognitive behavioural therapy (CBT) in 469 individuals with 46 months follow-up. Results were consistent with a beneficial CBT treatment effect. The MI estimates are closer to the null than the CCA estimate, whereas the TM estimate was further from the null. We propose using the TM estimator as a sensitivity analysis for data where it is suspected that extreme outcome values are missing.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN38231611Funding StatementAH, TP and KT were supported by the Integrative Epidemiology Unit, which receives funding from the UK Medical Research Council and the University of Bristol (MC UU 00011/3). At the beginning of this project. JB's research at the University of Exeter is funded by a UKRI Expanding Excellence in England (E3) award. KHW was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund [204813/Z/16/Z] and is now affiliated to the Integrative Cancer Epidemiology Programme (ICEP), which is supported by a Cancer Research UK programme grant (C18281/A19169) and works within the Medical Research Council Integrative Epidemiology Unit (MC UU 00011/1-7). NW: The CoBalT trial was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme (project number 06/404/02).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This paper made use of data from the CoBalT follow-up study. Ethical approval for the follow-up study was given by the National Research Ethics Service Committee West Midlands, Edgbaston (reference number 13/WM/0149). Research governance approvals were obtained from the relevant local Research Ethics Committees and Clinical Commissioning Groups or Health Boards covering the three study sites (Bristol, Exeter, and Glasgow). The protocol is available online.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the CoBalT trial is available on request from the authors ER -